Arcadia Biosciences Inc (RKDA) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance has been significantly declining, with revenue, net income, EPS, and gross margin all showing negative growth trends in the latest quarter. Additionally, there are no positive trading trends, news catalysts, or strong technical signals to support a buy decision. The lack of recent analyst ratings, congressional trading data, and valuation data further limits confidence in this stock as a long-term investment.

Technical Analysis

The MACD is positive and expanding, suggesting a mild bullish momentum. However, the RSI is neutral at 65.934, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 1.942) in pre-market, which could limit immediate upside potential.

Positive Catalysts

NULL identified. No recent news, trading trends, or significant technical signals to suggest a positive catalyst.

Neutral/Negative Catalysts

The company's financial performance has significantly deteriorated in the latest quarter, with revenue, net income, EPS, and gross margin all showing substantial YoY declines. Additionally, there is no recent news or trading activity to suggest a reversal in sentiment.

Financial Performance

In Q3 2025, Arcadia Biosciences reported a revenue decline of -15.29% YoY to $1,302,000. Net income dropped by -153.10% YoY to $856,000, and EPS fell by -152.54% YoY to 0.62. Gross margin also declined by -25.14% YoY to 32.1%. These figures indicate significant financial underperformance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target updates available.

Analyst Rating

Wall Street analysts forecast RKDA stock price to rise

Buy

Hold

Sell

Current: 1.953

Low

Averages

High